Sushil Kumar Sharma is a prominent inventor based in West Orange, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating proliferative diseases such as cancer. With a total of 10 patents to his name, Sharma's work has the potential to impact the lives of many patients.

Latest Patents

Among his latest patents, Sharma has developed a compound known as (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-4-(4-fluorobenzoyl)-thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl)-2-methylamino-propionamide, or pharmaceutically acceptable salts thereof. This invention is directed towards treating proliferative diseases, including cancer, in mammals. Another notable patent involves SMAC peptidometics, which are useful as IAP inhibitors, aimed at the same therapeutic area.

Career Highlights

Sushil Kumar Sharma is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to collaborate with other talented professionals in the field, further enhancing his contributions to pharmaceutical innovations.

Collaborations

Some of his notable coworkers include Christopher Sean Straub and Run-Ming David Wang. Their collaborative efforts have likely contributed to the advancement of research and development in their respective projects.

Conclusion

Sushil Kumar Sharma's innovative work in the pharmaceutical industry, particularly in cancer treatment, showcases his dedication to improving healthcare outcomes. His numerous patents reflect his expertise and commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.